The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD

被引:100
作者
Cazzola, M
Di Marco, F
Santus, P
Boveri, B
Verga, M
Matera, MG
Centanni, S
机构
[1] A Cardarelli Hosp, Dept Resp Med, Unit Pneumol & Allergol, I-80121 Naples, Italy
[2] Univ Milan, San Paolo Hosp, Resp Med Unit, Milan, Italy
[3] Univ Naples 2, Dept Expt Med, Pharmacol Unit, Naples, Italy
关键词
chronic obstructive pulmonary disease; pulmonary function; formoterol; tiotropium; combination therapy;
D O I
10.1016/j.pupt.2003.09.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this double-blind, double-dummy, cross-over, randomized, pilot study was to compare the acute bronchodilator efficacy of a single dose of formoterol with that of tiotropium in patients with stable chronic obstructive pulmonary disease (COPD). Because the potential of tiotropium for additive effects is yet unknown, the acute effects of adding this anticholinergic agent to formoterol were also explored. A total of 20 outpatients with stable COPD were enrolled. Single doses of 12 mug formoterol, 18 mug tiotropium, and 12 mug formoterol + 18 mug tiotropium were given. Serial measurements of FEV1 were performed over 24 h. Formoterol, either alone or in combination with tiotropium, elicited a significantly faster onset of action and showed a trend for a greater maximum bronchodilation than tiotropium alone. At 24 h, mean FEV1 continued to be significantly higher than pre-dosing value following tiotropium and formoterol + tiotropium. These findings indicate that formoterol and tiotropium have different profiles that make both agents attractive alternatives in the treatment of stable COPD. Since tiotropium ensures prolonged bronchodilation, whereas formoterol adds fast onset and a greater peak effect, the two drugs appear complementary. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:35 / 39
页数:5
相关论文
共 20 条
[1]  
[Anonymous], 1987, Am Rev Respir Dis, V136, P1285
[2]  
[Anonymous], 1992, Medical uses of statistics, DOI DOI 10.1201/9780429187445
[3]  
Barnes PJ, 2000, CHEST, V117, P63
[4]   Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD [J].
Brusasco, V ;
Hodder, R ;
Miravitlles, M ;
Korducki, L ;
Towse, L ;
Kesten, S .
THORAX, 2003, 58 (05) :399-404
[5]   Long-acting β2 agonists in the management of stable chronic obstructive pulmonary disease [J].
Cazzola, M ;
Donner, CF .
DRUGS, 2000, 60 (02) :307-320
[6]  
CAZZOLA M, 2003, IN PRESS CHEST
[7]  
CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
[8]   In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium - A 3-week, randomized, double-blind, within-patient, multicenter study [J].
D'Urzo, AD ;
De Salvo, MC ;
Ramirez-Rivera, A ;
Almeida, J ;
Sichletidis, L ;
Rapatz, G ;
Kottakis, J .
CHEST, 2001, 119 (05) :1347-1356
[9]   Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease [J].
Dahl, R ;
Greefhorst, LAPM ;
Nowak, D ;
Nonikov, V ;
Byrne, AM ;
Thomson, MH ;
Till, D ;
Della Cioppa, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (05) :778-784
[10]   A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol [J].
Donohue, JF ;
van Noord, JA ;
Bateman, ED ;
Langley, SJ ;
Lee, A ;
Witek, TJ ;
Kesten, S ;
Towse, L .
CHEST, 2002, 122 (01) :47-55